Patent intelligence · US
US 12072338
Pharmaceutical peptides for the treatment of inflammatory diseases
Pharmaceutical peptides for the treatment of inflammatory diseases
Patent details — US 12072338
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 27, 2024
- Expiration
- Aug 22, 2044
- Applicant
- PROTAGONISTS LTD.
- Claims
- 7
- CPC classes
- A61K, A61K38/00, A61P, A61P19/02
Quick answer
US 12072338 (Pharmaceutical peptides for the treatment of inflammatory diseases) is held by PROTAGONISTS LTD.. Status: granted. Granted Aug 27, 2024. Expires Aug 22, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PROTAGONISTS LTD.
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K38/00, A61P, A61P19/02
More from PROTAGONISTS LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12269856
Hepcidin analogues and uses thereof
granted -
US 12234300
Conjugated hepcidin mimetics
granted -
US 12018057
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
granted -
US 11939361
Compositions of peptide inhibitors of Interleukin-23 receptor
granted -
US 11884748
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
granted -
US 11845808
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
granted -
US 11840581
α4β7 thioether peptide dimer antagonists
granted
Frequently asked questions
What is US patent 12072338?
US 12072338 (Pharmaceutical peptides for the treatment of inflammatory diseases) is held by PROTAGONISTS LTD.. Status: granted. Granted Aug 27, 2024. Expires Aug 22, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12072338?
PROTAGONISTS LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 33 pharmaceutical patents for this assignee.
When does US 12072338 expire?
Our index shows an expiration date of Aug 22, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.